Skip to content


Reblozyl (luspatercept) is a protein pharmaceutical. Luspatercept was first approved as Reblozyl on 2019-11-08. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, beta-thalassemia, and myelodysplastic syndromes. It is known to target growth/differentiation factor 11, bone morphogenetic protein 10, growth/differentiation factor 2, growth/differentiation factor 8, and bone morphogenetic protein 6.
Trade Name Reblozyl
Common Name Luspatercept
Indication anemia, beta-thalassemia, myelodysplastic syndromes
Drug Class Receptor molecules, native or modified: transforming growth factor
Get full access now